Six months after the treatment commenced, a decrease in the TSPO/mitochondria ratio occurred, resembling that of the healthy controls in 24/30 CLL patients (Fig. 1A). This evidence concerns the gene TSPO and B-cell chronic lymphocytic leukemia.